Management of acute antipsychotic-induced extrapyramidal syndromes

CNS Drugs

Volumn 5, Issue SUPPL. 1, 1996, Pages 21-35

  Remington, Gary ^a,b   Bezchlibnyk Butler, Kalyna ^a  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; ANTIPARKINSON AGENT; ATENOLOL; BENZATROPINE; BENZODIAZEPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIPERIDEN; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLONIDINE; CLOZAPINE; CYPROHEPTADINE; DIAZEPAM; DIPHENHYDRAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; LORAZEPAM; NADOLOL; NEUROLEPTIC AGENT; PINDOLOL; PROPRANOLOL; RISPERIDONE; RITANSERIN;

AKATHISIA; EXTRAPYRAMIDAL SYNDROME; HUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0029736932     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-199600051-00005     Document Type: Review

References (212)

1. Deniker P. The neuroleptics: a historical survey. Acta Psychiatr Scand 1990; 82 Suppl. 358: 83-7
2. Seeman P. Schizophrenia as a brain disease: the dopamine receptor story. Arch Neurol 1993; 50: 1093-5
3. Marder SR, Wirshing WC, Van Putten T. Drug treatment of schizophrenia: overview of recent research. Schizophr Res 1991; 4: 81-90
4. Zito JM, Craig TJ, Wanderung J, et al. Pharmaco-epidemiology in 136 hospitalized schizophrenic patients. Am J Psychiatry 1987; 144: 778-82
5. Reardon GT, Rifkins A, Schwartz A, et al. Changing patterns of neuroleptic dosage over a decade. Am J Psychiatry 1989; 146: 726-9
6. Remington GJ, Prendergast P, Bezchlibnyk-Butler KZ. Dosaging patterns in schizophrenia with depot, oral and combined neuroleptic therapy. Can J Psychiatry 1993; 38: 159-61
7. Baldessarini RJ, Kando JC, Centorrino F. Hospital use of antipsychotic agents in 1989 and 1993: stable dosing with decreased length of stay. Am J Psychiatry 1995; 152: 1038-44
8. Casey D. Neuroleptic side effects: acute extrapyramidal syndromes and tardive dyskinesia. In: Casey DE, Christensen AV, editors. Psychopharmacology: Current Trends. Berlin: Springer-Verlag, 1988: 74-93
9. Van Putten T. Why do schizophrenic patients refuse to take their drugs? Arch Gen Psychiatry 1974; 31: 67-72
10. Barach E, Dubin LM, Tomlanovich MC, et al. Dystonia presenting as upper airway obstruction. J Emerg Med 1989; 7: 237-40
11. Koek RJ, Pi EH. Acute laryngeal dystonic reactions to neuroleptics. Psychosomatics 1989; 30: 359-64
12. Borison RL, Diamond DI. Neuropharmacology of the extrapyramidal system. J Clin Psychiatry 1987; 48 Suppl.: 7-12
13. Marsden CD, Jenner P. The pathophysiology of extrapyramidal side-effects of neuroleptic drugs. Psychol Med 1980; 10: 55-72
14. Seeman P, Van Tol HHM. Dopamine receptor pharmacology. Curr Opin Neurol Neurosurg 1993; 6: 602-8
15. Casey DE. Dopamine D1 and D2 agonists and antagonists in cebus monkeys [abstract]. Proc Soc Biol Psychiatry 1988: 13
16. 2 dopamine receptor occupancy in patients with classical neuroleptics and clozapine. Arch Gen Psychiatry 1992; 49: 538-44
17. Gerlach J, Peacock L. Motor and mental side effects of clozapine. J Clin Psychiatry 1994; 55 Suppl. B: 107-9
18. Kurz M, Hummer M, Oberbauer H, et al. Extrapyramidal side effects of clozapine and haloperidol. Psychopharmacology 1995; 118: 52-6
19. Bollen CA, De Cuyper CH, Enemun E, et al. Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double-blind comparative study. Acta Psychiatr Scand 1992; 85: 295-305
20. Chouinard G, Jones B, Remington G, et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993; 13: 25-40
21. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994; 151: 825-35
22. Peuskens J. Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Br J Psychiatry 1995; 166: 712-26
23. 2 receptor binding in risperidone-treated schizophrenic patients. J Clin Psychopharmacol 1995; 15 Suppl. 1: 19S-23S
24. 2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: a PET study. Life Sci 1995; 57: 103-8
25. Borison RL. Amantadine in the management of extrapyramidal side effects. Clin Neuropharmacol 1983; 6 Suppl. 1: S57-63
26. Ehlert FJ, Roeske WR, Yamamura HI. Molecular biology, pharmacology, and brain distribution of subtypes of the muscarinic receptor. In: Bloom FE, Kupfer DJ, editors. Psychopharmacology: the fourth generation of progress. New York: Raven Press, 1995: 111-24
27. Bezchlibnyk-Butler KZ, Remington GJ. Antiparkinsonian drugs in the treatment of neuroleptic-induced extrapyramidal symptoms. Can J Psychiatry 1994; 39: 74-84
28. Modell JG, Tandon R, Beresford TP. Dopaminergic activity of the antimuscarinic antiparkinsonian agents. J Clin Psychopharmacol 1989; 9: 347-51
29. Flaherty JA, Bellur SN. Mental side effects of amantadine therapy: its spectrum and characteristics in a normal population. J Clin Psychiatry 1981; 42: 344-5
30. Rego MD, Giller Jr EL. Mania secondary to amantadine treatment of neuroleptic-induced hyperprolactinemia. J Clin Psychiatry 1989; 50: 143-4
31. Nestelbaum Z, Siris SG, Rifkin A, et al. Exacerbation of schizophrenia associated with amantadine. Am J Psychiatry 1986; 143: 1170-1
32. McNamara P, Durso R. Reversible pathological jealousy (Othello syndrome) associated with amantadine. J Geriatr Psychiatry Neurol 1991; 4: 157-9
33. Wilcox JA, Tsuang J. Psychological effects of amantadine on psychotic subjects. Neuropsychobiology 1990; 23: 144-6
34. Cook PE, Dermer SW, McGurk T. Fatal overdose with amantadine. Can J Psychiatry 1986; 31: 757-8
35. Simpson DMI, Ramos F, Ramirez LF. Death of a psychiatric patient from amantadine poisoning. Am J Psychiatry 1988; 145: 267-8
36. McEvoy JP, McCue M, Spring B, et al. Effects of amantadine and trihexyphenidyl on memory in elderly normal volunteers. Am J Psychiatry 1987; 144: 573-7
37. McEvoy JP. A double-blind comparison of antiparkinson drug therapy: amantadine versus anticholinergics in 90 normal volunteers, with an emphasis on differential effects on memory function. J Clin Psychiatry 1987; 48 Suppl. 9: 20-3
38. DiMascio A, Bernardo DL, Greenblatt DJ, et al. A controlled trial of amantadine in drug-induced extrapyramidal disorders. Arch Gen Psychiatry 1976; 33: 599-602
39. Fann WE, Lake CR. Amantadine versus trihexyphenidyl in the treatment of neuroleptic-induced parkinsonism. Am J Psychiatry 1976; 133: 940-3
40. Stenson RL, Donlon PT, Meyer JE. Comparison of benztropine mesylate and amantadine HCl in neuroleptic-induced extrapyramidal symptoms. Compr Psychiatry 1976; 17: 763-8
41. Aranth J, Sangani H, Noonan JP. Amantadine in drug-induced extrapyramidal signs. Int J Clin Pharmacol Biopharm 1975; 11: 323-6
42. Silver H, Geraisy N, Schwartz M. No difference in the effect of biperiden and amantadine in parkinsonism- and tardive dyskinesia-type involuntary movements: a double-blind crossover, placebo-controlled study in medicated chronic schizophrenic patients. J Clin Psychiatry 1995; 56: 167-70
43. McEvoy JP, McCue M, Freter S. Replacement of chronically administered anticholinergic drugs by amantadine in out-patient management ot chronic schizophrenia. Curr Ther 1987; 9: 429-33
44. Neu C, DiMascio A, Demirgian E. Antiparkinsonian medication in the treatment of extrapyramidal side-effects: single or multiple doses. Curr Ther Res 1972; 4: 246-51
45. Van Putten T, Mutalipassi LR, Malkin MD. Phenothiazine induced decompensation. Arch Gen Psychiatry 1974; 30: 102-5
46. Friis T, Christensen TR, Gerlach J. Sodium valproate and biperiden in neuroleptic-induced akathisia, parkinsonism and hyperkinesia: a double-blind cross-over study with placebo. Acta Psychiatr Scand 1982; 67: 178-87
47. Van Putten T, May PRA, Marder SR. Akathisia with haloperidol and thiothixene. Arch Gen Psychiatry 1984; 41: 1036-9
48. American College of Neuropsychopharmacology - Food and Drug Administration Task Force. Neurological syndromes associated with antipsychotic drug use. Arch Gen Psychiatry 1973; 28: 463-7
49. Adler LA, Angrist B, Reiter S, et al. Neuroleptic-induced akathisia: a review. Psychopharmacology 1989; 97: 1-11
50. Fleischhacker WW, Roth SD, Kane JM. The pharmacologic treatment of neuroleptic-induced akathisia. J Clin Psychopharmacol 1990; 10: 12-21
51. Boodhoo JA, Sandler M. Anticholinergic antiparkinsonian drugs in psychiatry. Br J Hosp Med 1991 ; 46: 167-9
52. Pearlman CA. Akathisia as EPS. J Clin Psychiatry 1993; 54: 280
53. Braude WM, Barnes TRE, Gore SM. Clinical characteristics of akathisia: a systematic investigation of acute psychiatric inpatient admissions. Br J Psychiatry 1983; 143: 139-50
54. Van Putten T. The many faces of akathisia. Compr Psychiatry 1975; 16: 43-7
55. Duncan E, Angrist B, Adler L, et al. Pharmacologic challenge in akathisia variants. Schizophr Res 1989; 2: 242
56. Lipinski Jr JF, Keck PE, McElroy SL. ß-adrenergic antagonists in psychosis: is improvement due to treatment of neuroleptic-induced akathisia? J Clin Psychopharmacol 1988; 8: 409-16
57. Dahlstrom A, Fuxe K. Evidence for the existence of monoamine neurons in the central nervous system. Acta Physiol Scand 1965; 64: 37-85
58. Blin O, Durup M, Pailhous J, et al. Akathisia, motility, and locomotion in healthy volunteers. Clin Neuropharmacol 1990; 13: 426-35
59. Kulik AV, Wilbur R. Case report of propranolol (Inderal) pharmacotherapy for neuroleptic-induced akathisia and tremor. Prog Neuropsychopharmacol Biol Psychiatry 1983; 7: 223-5
60. Lipinski JF, Zubenko GS, Barreira P, et al. Propranolol in the treatment of neuroleptic-induced akathisia. Lancet 1983; 1: 685-6
61. Lipinski Jr JF, Zubenko GS, Cohen BM, et al. Propranolol in the treatment of neuroleptic-induced akathisia. Am J Psychiatry 1984; 141: 412-5
62. Adler L, Angrist B, Peselow E, et al. A controlled assessment of propranolol in the treatment of neuroleptic-induced akathisia. Br J Psychiatry 1986; 149: 42-5
63. Yassa R, Iskandar H, Nastase C. Propranolol in the treatment of tardive akathisia: a report of two cases. J Clin Psychopharmacol 1988; 8: 283-5
64. Kramer MS, Gorkin RA, DiJohnson C, et al. Propranolol in the treatment of neuroleptic-induced akathisia (NIA) in schizophrenia: a double-blind, placebo-controlled study. Biol Psychiatry 1988; 24: 823-7
65. Kramer MS, Gorkin R, DiJohnson C. Treatment of neuroleptic-induced akathisia with propranolol: a controlled replication study. Hillside J Clin Psychiatry 1989; 11: 107-19
66. Chandler JD. Propranolol treatment of akathisia in Tourette's syndrome. J Am Acad Child Adolesc Psychiatry 1990; 29: 475-7
67. Fleischhacker WW. Propranolol for fluoxetine-induced akathisia. Biol Psychiatry 1991; 30: 531-2
68. Irwin M, Sullivan G, Van Putten T. Propranolol as a primary treatment of neuroleptic-induced akathisia. Hillside J Clin Psychiatry 1988; 10: 244-50
69. Adler LA, Angrist B, Fritz P, et al. Lack of efficacy of d-propranolol in neuroleptic-induced akathisia. Neuropsychopharmacology 1991; 4: 109-15
70. Zubenko GS, Lipinski Jr JF, Cohen BM, et al. Comparison of metoprolol and propranolol in the treatment of akathisia. Psychiatry Res 1984; 11: 143-9
71. Dupuis B, Catteau J, Dumon J-P, et al. Comparison of propranolol, sotalol, and betaxolol in the treatment of neuroleptic-induced akathisia. Am J Psychiatry 1987; 144; 802-5
72. 2-receptor Mocker in neuroleptic-induced akathisia. Psychiatry Res 1989; 27: 1-4
73. Adler LA, Duncan E, Kim A, et al. Akathisia: selective β-blockers and rating instruments. Psychopharmacol Bull 1989; 25: 451-6
74. Kim A, Adler L, Angrist B, et al. Efficacy of low-dose metoprolol in neuroleptic-induced akathisia. J Clin Psychopharmacol 1989; 9: 294-6
75. Dumon J-P, Catleau J, Lanvin F, et al. Randomized, double-blind, crossover, placebo-controlled comparison of propranolol and betaxolol in the treatment of neuroleptic-induced akathisia. Am J Psychiatry 1992; 149: 647-50
76. Reiter S, Adler L, Angrist B, et al. Atenolol and propranolol in neuroleptic-induced akathisia. J Clin Psychopharmacol 1987; 7: 279-80
77. Wells BG, Cold JA, Marken PA, et al. A placebo-controlled trial of nadolol in the treatment of neuroleptic-induced akathisia. J Clin Psychiatry 1991; 52: 255-60
78. Ratey JJ, Sorgi P, Polakoff S. Nadolol as a treatment for akathisia. Am J Psychiatry 1985; 142: 640-2
79. Dupuis BA, Catteau J, Dumon JP, et al. β-blockers in neuroleptic-induced akathisia: Dr Dupuis and associates reply. Am J Psychiatry 1988; 145: 900
80. Adler LA, Angrist B, Weinreb H, et al. Studies on the time course and efficacy of β-blockers in neuroleptic-induced akathisia and the akathisia of idiopathic Parkinson's disease. Psychopharmacol Bull 1991; 27: 107-11
81. Adler LA, Reiter S, Corwin J, et al. Differential effects of propranolol and bezodiazepines in patients with neuroleptic-induced akathisia. Psychopharmacol Bull 1987; 23: 519-21
82. Adler LA, Reiter S, Corwin J, et al. Neuroleptic-induced akathisia: propranolol versus benztropine. Biol Psychiatry 1988; 23: 209-14
83. Hermesh H, Molcho A, Munitz H. Successful propranolol therapy for neuroleptic-induced akathisia resistant to anticholinergic and benzodiazepine drugs. Clin Neuropharmacol 1988; 4: 369-72
84. Dorevitch A, Durst R, Ginath Y. Propranolol in the treatment of akathisia caused by antipsychotic drugs. South Med J 1991; 84: 1505-6
85. Adler LA, Peselow E, Rosenthal M, et al. A controlled comparison of the effects of propranolol, benztropine, and placebo on akathisia: an interim analysis. Psychopharmacol Bull 1993; 29: 283-6
86. Silver JM, Yudofsky SC, Kogan M, et al. Elevation of thioridazine plasma levels by propranolol. Am J Psychiatry 1986; 143: 1290-2
87. Comaty JE. Propranolol treatment of neuroleptic-induced akathisia. Psychiatr Ann 1987; 17: 150-5
88. Reiter S, Adler L, Erle S, et al. Neuroleptic induced akathisia treated with pindolol. Am J Psychiatry 1987; 143: 383-4
89. Adler LA, Reiter S, Angrist B, et al. Pindolol and propranolol on neuroleptic-induced akathisia. Am J Psychiatry 1987; 144: 1241-2
90. Kabes J, Sikora J, Pisvejc J, et al. Effect of piracetam on extrapyramidal side effects induced by neuroleptic drugs. Int Pharmacopsychiat 1982; 17: 185-92
91. Bartels M, Heide K, Mann K, et al. Treatment of akathisia with lorazepam: an open clinical trial. Pharmacopsychiatry 1987; 20: 51-3
92. Kutcher SP, Mackenzie S, Galarraga W, et al. Clonazepam treatment of adolescents with neuroleptic-induced akathisia. Am J Psychiatry 1987; 144: 823-4
93. Horiguchi J, Nishimatsu O, Inami Y. Successful treatment with clonazepam for neuroleptic-induced akathisia. Acta Psychiatr Scand 1989; 80: 106-7
94. Kutcher S, Williamxon P, Mackenzie S, et al. Successful clonazepam treatment of neuroleptic-induced akathisia in older adolescents and young adults: a double-blind, placebo-controlled trial. J Clin Psychopharmacol 1989; 9: 403-6
95. Gagrat D, Hamilton J, Belmaker RH. Intravenous diazepam in the treatment of neuroleptic-induced acute dystonia and akathisia. Am J Psychiatry 1978; 135: 1232-3
96. Donlon T. The therapeutic use of diazepam for akathisia. Psychosomatics 1973; 14: 222-5
97. Director KL, Muniz CE. Diazepam in the treatment of extrapyramidal symptoms: a case report. J Clin Psychiatry 1982; 43: 160-1
98. Moleman P, Schmitz PJM, Ladee GA. Extrapyramidal side effects and oral haloperidol: an analysis of explanatory patient and treatment characteristics. J Clin Psychiatry 1982; 43: 492-6
99. Adler L, Angrist B, Peselow E, et al. Efficacy of propranolol in neuroleptic-induced akathisia. J Clin Psychopharmacol 1985; 5: 164-6
100. Sachdev P, Kruk J. Clinical characteristics and predisposing factors in acute drug-induced akathisia. Arch Gen Psychiatry 1994; 51: 963-74
101. Zubenko GS, Cohen BM, Lipinski Jr JF, et al. Use of clonidine in treating neuroleptic-induced akathisia. Psychiatry Res 1984; 13: 253-9
102. Adler L, Angrist B, Peselow E, et al. Noradrenergic mechanisms in akathisia: treatment with propranolol and clonidine. Psychopharmacol Bull 1987; 23: 21-5
103. 2 antagonist ritanserin. Psychopharmacol Bull 1990; 26: 373-6
104. Fleischhacker WW, Miller CH, Ehrmann H. Ritanserin in the treatment of neuroleptic-induced akathisia. Schizophr Res 1990; 3: 47
105. Miller CH, Hummer M, Pycha R, et al. The effect of ritanserin on treatment-resistant neuroleptic-induced akathisia: case reports. Prog Neuropsychopharmacol Biol Psychiatry 1992; 16: 247-51
106. Weiss D, Aizenberg D, Hermesh H, et al. Cyproheptadine treatment in neuroleptic-induced akathisia. Br J Psychiatry 1995; 167: 483-6
107. Dewey SL, Smith GS, Logan J, et al. Serotonergic modulation of striatal dopamine measured with positron emission tomography (PET) and in vivo microdialysis. J Neurosci 1995; 15: 821-9
108. Lipinski Jr JF, Mallya G, Zimmerman P, et al. Fluoxetine-induced akathisia: clinical and theoretical implications. J Clin Psychiatry 1989; 50: 339-42
109. LaPorta LD. Sertraline-induced akathisia. J Clin Psychopharmacol 1993; 13: 219-20
110. Fischer P, Naske R. Akathisia-like motor restlessness in major depression responding to serotonin-reuptake inhibition. J Clin Psychopharmacol 1992; 12: 295-6
111. Kramer MS, DiJohnson C, Davis P, et al. L-tryptophan in neuroleptic-induced akathisia. Biol Psychiatry 1990; 27: 671-85
112. D'Mello DA, McNeil JA, Harris W. Buspirone suppression of neuroleptic-induced akathisia: multiple case reports. J Clin Psychopharmacol 1989; 9: 151-2
113. Brody D, Adler LA, Kim T, et al. Effects of buspirone in seven schizophrenic subjects. J Clin Psychopharmacol 1990; 10: 68-9
114. Goff DC, Midha KK, Brotman AW, et al. An open trial of buspirone added to neuroleptics in schizophrenic patients. J Clin Psychopharmacol 1991; 11: 193-7
115. Danel T, Servant D, Goudemand M. Amitriptyline in the treatment of neuroleptic-induced akathisia. Biol Psychiatry 1988; 23: 186-8
116. Botschev C, Muller-Spahn F, Straube A. Neuroleptic-induced akathisa: treatment with tramadol and amitriptyline. In: Stefanis CN, Soldatas CR, Rabavilas AD, editors. Psychiatry today: accomplishments and promises [abstract]. Amsterdam: Excerpta Medica, International Congress Series 899, 1989: 145
117. Hermesh H, Aizenberg D, Friedberg G, et al. Low-dose clomipramine for refractory acute neuroleptic-induced akathisia. In: Stefanis CN, Soldatas CR, Rabavilas AD, editors. Psychiatry today: accomplishments and promises [abstract]. Amsterdam: Excerpta Medica, International Congress Series 899, 1989: 226
118. Hermesh H, Aizenberg D, Friedberg G, et al. Low-dose clomipramine for refractory acute neuroleptic-induced akathisia: possible role of CNS serotonin in akathisia. In: Stefanis CN, Soldatas CR, Rabavilas AD, editors. Psychiatry: a world perspective. Vol 3. Amsterdam: Elsevier Science Publishers, 1990: 313-9
119. Ames D, Wirshing WC, Lee MA, et al. Selegiline in the treatment of akathisia, tardive dyskinesia, and negative schizophrenic symptoms. Schizophr Res 1992; 6: 110
120. Shalev A, Hermesh H, Munitz H. Severe akathisia causing neuroleptic failure: an indication for lithium therapy in schizophrenia? Acta Psychiatr Scand 1987; 76: 715-8
121. Gillman MA, Sandyk R, Lichtigfeld FJ. Evidence for underactivity of the opioid system in neuroleptic-induced akathisia. Psychiatry Res 1984; 13: 187
122. Walters AS, Hening A. Opioids a better treatment for acute than tardive akathisia: possible role for the endogenous opiate system in neuroleptic-induceds akathisia. Med Hypotheses 1989; 28: 1-2
123. Hermesh H, Aizenberg D, Friedberg G, et al. Electroconvulsive therapy for persistent neuroleptic-induced akathisia and parkinsonism: a case report. Biol Psychiatry 1992; 31: 407-11
124. World Health Organization. Prophylactic use of anticholinergics in patients on long-term neuroleptic treatment: a consensus statement. Br J Psychiatry 1990; 156: 412
125. Swett C, Cole JO, Shapiro S, et al. Extrapyramidal side effects in chlorpromazine recipients. Arch Gen Psychiatry 1977; 34: 942-3
126. DiMascio A, Demirgian E. Antiparkinson drug overuse. Psychosomatics 1970; 11: 596-601
127. Wada Y, Koshino Y, Yamaguchi N. Biperiden withdrawal in schizophrenic inpatients receiving long-term antipsychotic medication. Clin Neuropharmacol 1987; 10: 370-5
128. Comaty JE, Janicak PG, Rajaratnam J, et al. Is maintenance antiparkinsonian treatment necessary? Psychopharmacol Bull 1990; 26: 267-70
129. McEvoy JP. Neuroleptic dose and the need for prophylactic anticholinergic drugs. J Clin Psychiatry 1986; 47: 611
130. Lake CR, Casey DE, McEvoy JP, et al. The 'pros' and 'cons' of anticholinergic prophylaxis. Psychopharmacol Bull 1986; 22: 981-4
131. Barnes TRE. Comment on the WHO consensus statement. Br J Psychiatry 1990; 156: 413-4
132. Stern TA, Anderson WH. Benztropine prophylaxis of dystonic reactions. Psychopharmacology 1979; 61: 261-2
133. Keepers GA, Clappison VJ, Casey DE. Initial anticholinergic prophylaxis for neuroleptic-induced extrapyramidal syndromes. Arch Gen Psychiatry 1983; 40: 1113-7
134. Sramek JJ, Simpson GM, Morrison RL. et al. Anticholinergic agents for prophylaxis of neuroleptic-induced dystonic reactions: a prospective study. J Clin Psychopharmacol 1986; 47: 305-9
135. Winslow RS, Stillner V, Coons DJ, et al. Prevention of acute dystonic reactions in patients beginning high-potency neuroleptics. Am J Psychiatry 1986; 143: 706-10
136. Boyer WF, Bakalar NH, Lake CR. Anticholinergic prophylaxis of acute haloperidol-induced acute dystonic reactions. J Clin Psychopharmacol 1987; 7: 164-6
137. Keepers GA, Casey DE. Prediction of neuroleptic-induced dystonia. J Clin Psychopharmacol 1987; 7: 342-5
138. Arana GW, Goff DC, Baldessarini RJ, et al. Efficacy of anticholinergic prophylaxis for neuroleptic-induced acute dystonia. Am J Psychiatry 1988; 145: 993-6
139. Goff DC, Arana GW, Greenblatt DJ, et al. The effect of benztropine on haloperidol-induced dystonia, clinical efficacy and pharmacokinetics: a prospective, double-blind trial. J Clin Psychopharmacol 1991; 11: 106-12
140. Manos N, Lavrentiadis G, Gkiouzepas J. Evaluation of the need for prophylactic antiparkinsonian medication in psychotic patients treated with neuroleptics. J Clin Psychiatry 1986; 47: 114-6
141. Aguilar EJ, Keshavan MS, Martinez-Quiles MD, et al. Predictors of acute dystonia in first-episode psychotic patients. Am J Psychiatry 1994; 151: 1819-21
142. Mallett P. Anticholinergic drugs in psychiatry. Int Clin Psychopharmacol 1989; 4: 261-71
143. Rifkin A, Quitkin F, Kane J, et al. Are prophylactic antiparkinsonian drugs necessary? Arch Gen Psychiatry 1978; 35: 483-9
144. Lavin MR, Rifkin A. Prophylactic antiparkinsonian drug use: I. Initial prophylaxis and prevention of extrapyramidal side effects. J Clin Pharmacol 1991; 31: 763-8
145. Bezchlibnyk-Butler K, Jeffries JJ, editors. Clinical handbook of psychotropic drugs. Toronto: Hogrefe & Huber, 1991
146. Cedarbaum JM. Clinical pharmacokinetics of antiparkinsonian drugs. Clin Pharmacokinet 1987; 13: 141-78
147. Goodman Gilman A, Rell TW, Nies AS, et al. editors. Goodman and Gilman's the pharmacological basis of therapeutics. 8th ed. New York: McGraw-Hill, 1993
148. Reynolds JEF, editor. Martindale: the extra pharmacopoeia, 30th ed. London: The Pharmaceutical Press, 1993
149. Nora JJ, Nora AH, Way GL. Cardiovascular maldevelopment associated with maternal exposure to amanladine. Lancet 1975; 2 (7935): 607
150. Friedhoff AJ, Miller JC. Prenatal psychotropic drug exposure and the development of central dopaminergic and cholinergic neurotransmitter systems. Monogr Neural Sci 1983; 9: 91-8
151. McEvoy JP. The clinical use of anticholinergic drugs as treatment for extrapyramidal side effects of neuroleptic drugs. J Clin Psychopharmacol 1983; 3: 288-302
152. Katz IR,Greenherg WH, Barr GA, et al. Screening for cognitive toxicity of anticholinergic drugs. J Clin Psychiatry 1985; 46: 323-6
153. Gelenberg AJ, Van Putten T, Lavori PW, et al. Anticholinergic effects on memory: benztropine versus amantadine. J Clin Psychopharmacol 1989; 9: 180-5
154. McEvoy JP. The dose-response relationship for memory impairment by anticholinergic drugs. Compr Psychiatry 1989; 30: 135-8
155. Silver H. Effect of antiparkinsonian drugs on memory in medicated chronic schizophrenics. Eur Neuropsychopharmacol 1994; 4: 392
156. Potamianos G, Kellett JM. Anticholinergic drugs and memory: the effects of benzhexol on memory in a group of geriatric patients. Br J Psychiatry 1982; 140: 470-2
157. Fayen M, Goldman MB, Moulthrop MA, et al. Differential memory function with dopaminergic versus anticholinergic treatment of drug-induced extrapyramidal symptoms. Am J Psychiatry 1988; 145: 483-6
158. Snyder S, Yamamura H. Antidepressants and the muscarinic acetylcholine receptor. Arch Gen Psychiatry 1977; 34: 236-9
159. Tune L, Coyle JT. Serum levels of anticholinergic drugs and impaired recent memory in chronic schizophrenic patients. Am J Psychiatry 1982; 139: 1460-2
160. Avissar S, Schreiber G. Muscarinic receptor subclassification and G-proteins: significance for lithium action in affective disorder and for the treatment of the extrapyramidal side effects of neuroleptics. Biol Psychiatry 1989; 26: 113-30
161. Larson HW, Pfenning MA, Richelson E. Selectivity of antimuscarinic compounds for muscarinic receptors of human brain and heart. Psychopharmacology 1991; 103: 162-5
162. Gelenberg AJ. Antiparkinson drug use. Biological Therapies in Psychiatry Newsletter 1979; 2: 5-7
163. Ayd Jr FJ. Abuse of anticholinergic drugs: an under-recognized problem. Int Drug Ther News 1985; 20: 1-2
164. Disalver SC. Antimuscarinic agents as substances of abuse: a review. J Clin Psychopharmacol 1988; 8: 14-22
165. Knable MB. Euphorigenic properties of anticholinergics. J Clin Psychiatry 1989; 50: 186
166. Wells BG, Marken PA, Rickman LA, et al. Characterizing anticholinergic abuse in community mental health. J Clin Psychopharmacol 1989; 9: 431-5
167. Brower KS. Smoking of prescription anticholinergic drugs. Am J Psychiatry 1987; 144: 383
168. Warnes H. Toxic psychosis due to antiparkinsonian drugs. Can Psychiatr Assoc J 1967; 12: 323-6
169. Brizer DA, Manning DW. Delirium induced by poisoning with anticholinergic agents. Am J Psychiatry 1982; 139: 1343-4
170. Trend P, Trimble M, Wessely S. Schizophrenic psychosis associated with benzhexol (Artane) therapy. J Neurol Neurosurg Psychiatry 1989; 52: 1115
171. Woods JH, Katz JL, Winger G. Use and abuse of benzodiazepines: issues relevant to prescribing. JAMA 1988; 260: 3476-80
172. Salzman C, The APA task force report on benzodiazepine dependence, toxicity, and abuse. Am J Psychiatry 1991; 148: 151-2
173. Luchins DJ, Freed WJ, Wyatt RJ. The role of cholinergic supersensitivity in the medical symptoms associated with the withdrawal of antipsychotic drugs. Am J Psychiatry 1980; 137: 1395-8
174. Lawrence J. Reactions to withdrawal of antidepressants, antiparkinsonian drugs, and lithium. Psychosomatics 1985; 26: 869-77
175. Tandon R, Dutchak D, Greden JF. Cholinergic syndrome following anticholinergic withdrawal in a schizophrenic patient abusing marijuana. Br J Psychiatry 1989; 154: 712-4
176. Jellinek T, Gardus G, Cole JO. Adverse effects of antiparkinsonian drug withdrawal. Am J Psychiatry 1981; 12: 1567-71
177. Goldstein JM, Tsuang MT. Gender and schizophrenia: an introduction and synthesis of findings. Schizophr Bull 1990; 16: 179-83
178. Jellinek T, Gardos G, Cole JO. Adverse effects of antiparkinsonian drug withdrawal. Am J Psychiatry 1981; 138: 1567-71
179. Gibb WRG, Lees AJ. The neuroleptic malignant syndrome - a review. Q J Med 1985; 56: 421-9
180. Abbott RJ, Loizou LA. Neuroleptic malignant syndrome. Br J Psychiatry 1986; 148: 47-51
181. Sakkas P, Davis JM, Janicak PG, et al. Drug treatment of the neuroleptic malignant syndrome. Psychopharmacol Bull 1991; 27: 381-4
182. Kellam AMP. The neuroleptic malignant syndrome, so-called: a survey of the world literature. Br J Psychiatry 1987; 150: 752-9
183. Gerlach J, Thorsen K. The movement pattern of oral tardive dyskinesia in relation to anticholinergic and antidopaminergic treatment. Int Pharmacopsychiat 1976; 11: 1-7
184. Donlon PT. Stenson RL. Neuroleptic-induced extra-pyramidal symptoms. Dis Nerv Syst 1976; 37: 629-35
185. Chouinard G, Annable L, Ross-Chouinard A, et al. Factors related to tardive dyskinesia. AmJ Psychiatry 1979; 136: 79-83
186. Chouinard G, Steinberg S. Type 1 tardive dyskinesia induced by anticholinergic drugs, dopamine agonists and neuroleptics. Prog Neuropsychopharmacol Biol Psychiatry 1982; 6: 571-8
187. Greil W, Haag H, Rossnagl G, et al. Effect of anticholinergics on tardive dyskinesia: a controlled discontinuation study. Br J Psychiatry 1984; 145: 304-10
188. Yassa R. Tardive dyskinesia and anticholinergic drugs: a critical review of the literature. Encephale 1988; 14: 233-9
189. Burnett GB, Prange Jr AS, Welsa IC, et al. Adverse effects of anticholinergic antiparkinsonian drugs in tardive dyskinesia. Neuropsychobiology 1980; 6: 109-20
190. Chouinard G, Amiable L, Mercier P, et al. Long-term effects of L-dopa and procyclidine on neuroleptic-induced extra-pyramidal and schizophrenic symptoms. Psychopharmacol Bull 1987; 23: 221-6
191. Chouinard G, Annahle L, Ross-Chouinard A, et al. A 5-year prospective longitudinal study of tardive dyskinesia: factors predicting appearance of new cases. J Clin Psychopharmacol 1988; 8: 21S-26S
192. Casey DE. Neuroleptic drug-induced extrapyramidal syndromes and tardive dyskinesia. Schizophr Res 1991; 4: 109-20
193. Andrew HG. Clinical relationship of extrapyramidal symptoms and tardive dyskinesia. Can J Psychiatry 1994; 39 Suppl. 2: 76S-80
194. Rivera-Calimlim L, Castaneda L, Lasagna L. Effects of mode of management on plasma chlorpromazine in psychiatric patients. Clin Pharmacol Ther 1973; 14: 978-86
195. Chan TL, Sakalis G, Gershon S. Some aspects of chlorpromazine metabolism in humans. Clin Pharmacol Ther 1973; 14: 133
196. Ayd Jr FJ. Do antiparkinson drugs interfere with the therapeutic effects of neuroleptics? Int Drug Ther News 1974; 9: 29-32
197. Loga S, Curry S, Lader M. Interactions of orphenadrine and phenobarbitone with chlorpromazine: plasma concentrations and effects in man. J Clin Pharmacol 1975; 2: 197-208
198. Rivera-Calimlim L, Nasrallah H, Strauss J, et al. Clinical response and plasma levels: effects of dose, dosage schedules, and drug interactions on plasma chlorpromazine levels. Am J Psychiatry 1976; 133: 646-52
199. Chouinard G, Annable L, Cooper S. Antiparkinsonian drug administration and plasma levels of penfluridol, a new long-acting neuroleptic. Commun Psychopharmacol 1977; 1: 325-31
200. Gautier J, Jus A, Villeneuve A, et al. Influence of the antiparkinsonian drugs on the plasma levels of neuroleptics. Biol Psychiatry 1977; 12: 389-99
201. Rockland L, Cooper T, Schwartz F, et al. Effects of trihexyphenidyl on plasma chlorpromazine in young schizophrenics. Can J Psychiatry 1990; 35: 604-7
202. El-Yousef MK, Manier DH. The effect of benztropine mesylate on plasma levels of butaperazine maleate. Am J Psychiatry 1974; 131: 471-2
203. Hansen LB, Elley J, Christensen TR, et al. Plasma levels of perphenazine and its major metabolites during simultaneous treatment with anticholinergics. Br J Clin Pharmacol 1979; 7: 75-80
204. Simpson GM, Cooper TB, Bark N, et al. Effect of antiparkinsonian medication on plasma levels of chlorpromazine. Arch Gen Psychiatry 1980; 37: 205-8
205. Johnstone EC, Crow TJ, Ferrier N, et al. Adverse effects of anticholinergic medication on positive schizophrenic symptoms. Psychol Med 1983; 13: 513-27
206. Hitri A, Craft RB, Sethi R, et al. Drug levels and antiparkinsonian drugs in neuroleptic-treated schizophrenic patients. Clin Neuropharmacol 1987; 10: 261-71
207. Goff DC, Amico E, Dreyfuss D, et al. A placebo-controlled trial of trihexyphenidyl in unmedicated patients with schizophrenia. Am J Psychiatry 1994; 151: 429-31
208. Tandon R, Mann NA, Eisner WH, et al. Effect of anticholinergic medication on positive and negative symptoms in medication-free schizophrenic patients. Psychiatry Res 1989; 31: 235-41
209. Tandon R, Greden JF, Silk KR. Treatment of negative schizophrenic symptoms with trihexyphenidyl. J Clin Psychopharmacol 1988; 8: 212-5
210. Fisch RZ. Trihexyphenidyl abuse: therapeutic implications for negative symptoms of schizophrenia. Acta Psychiatr Scand 1987; 75: 91-4
211. Carpenter Jr WT, Heinrichs DW, Wagman AMI. Deficit and nondeficit forms of schizophrenia: the concept. Am J Psychiatry 1988; 145: 578-83
212. Carpenter Jr WT. Serotonin-dopamine antagonists and treatment of negative symptoms. J Clin Psychopharmacol 1995; 15 Suppl. 1: 30S-35